Trials are more complex, expensive, and harder to deliver. Recruitment delays cost millions. Sites are overburdened. Patients still face barriers to participation. Evidence requirements are expanding, while teams must prioritise budgets and adapt to shifting regulations.
AI, predictive analytics, decentralized models, and site intelligence promise faster recruitment and more scalable evidence generation.
But the challenge is not whether innovation is possible. It’s whether leaders can embed it across portfolios, prove impact, and turn fragmented pilots into repeatable, enterprise-wide change.
Future success will stem from leaders who design smarter trials, build community trust earlier, empower sites strategically, and use technology to analyse evidence faster.
Reuters Events: Pharma Clinical Innovation USA 2026 is the executive forum where clinical leaders convene to answer the pressing question: how do we build smarter, faster, scalable trials that deliver better evidence and greater patient impact?
Leave with practical strategies and partnerships to strengthen trial performance and future-proof clinical portfolios.
Events like Reuters Pharma Clinical Innovation support the connection of patient centered people and teams to learn and advance together. It’s essential to have these opportunities if we are truly committed to making big changes for patients.
– Laurie Meyers, Executive Director, Engagement and Experience Design, Genentech
